On February 26, 2025, Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, announced the initial closing of a $350.7 million Series D financing. The round was led by Eikon’s existing investors, with participation from new investors. Wilson Sonsini Goodrich & Rosati represented certain of the investors in the transaction.

The investment syndicate is composed of top mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms, including Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, Inc., and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others.

Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma. In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers.

The Wilson Sonsini team that advised the investors on the transaction included Ken Clark, Christina Poulsen, Jacie Valentine, and Jake Morales.

For more information, please see Eikon’s news release.